Corcept Therapeutics reported its financial results for the second quarter ended June 30, 2025, with net product revenue reaching $194.4 million, an increase from $163.8 million in the second quarter of 2024. However, diluted net income per common share was $0.29, a slight decrease from $0.32 in the prior year period.
The company revised its 2025 revenue guidance to a range of $850 million to $900 million, down from the previous range of $900 million to $950 million. This adjustment was attributed to operational challenges with its specialty pharmacy vendor, whose capacity was outpaced by the robust demand for Corcept's therapies, leading to dispensing delays.
Despite the temporary operational hurdles, Corcept highlighted continued strong underlying demand, with a record number of new prescribers and patients receiving treatment in its hypercortisolism business. The company expects improved performance from its current vendor and the addition of a second pharmacy to mitigate these issues in coming quarters, alongside ongoing pipeline advancements.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.